|

Elotuzumab Clinical Trials

10 actively recruiting trials across 9 locations

Also known as: BMS 901608, BMS-901608, BMS901608, Empliciti, Empliciti® +5 more

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 4Phase 1/2: 4

Top Sponsors

  • Yale University1
  • Regeneron Pharmaceuticals1
  • Pfizer1
  • Omar Nadeem, MD1
  • Medical College of Wisconsin1

Indications

  • Cancer10
  • Multiple Myeloma7
  • Recurrent Multiple Myeloma2
  • Refractory Multiple Myeloma2
  • Relapsed Refractory Multiple Myeloma (RRMM)1

Birmingham, Alabama2 trials

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

The University of Alabama at Birmingham

Phase 2
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

University of Alabama at Birmingham - Main /ID# 261434

Phase 3

Mobile, Alabama1 trial

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Infirmary Cancer Care

Phase 3

Gilbert, Arizona1 trial

Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Clovis, California1 trial

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

UCSF Fresno

Phase 3

Los Angeles, California1 trial

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

University of California Los Angeles (UCLA)

Phase 3

New Haven, Connecticut1 trial

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

Yale New Haven Hospital

Phase 1/2

Boston, Massachusetts1 trial

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Brigham and Women's Hospital

Phase 1/2

Rochester, Minnesota1 trial

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Mayo Clinic in Rochester

Phase 1/2

Columbus, Ohio1 trial

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.